← Back to Search

Somatostatin Analog

Low dose SRL + weekly Pegvisomant for Acromegaly

N/A
Waitlist Available
Led By Shlomo Melmed, MD
Research Sponsored by Cedars-Sinai Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights

Study Summary

This trial will compare the effectiveness of two different combinations of drugs to see if a lower dose of one drug can achieve the same results as a higher dose of the same drug.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cost Effectiveness

Trial Design

3Treatment groups
Active Control
Group I: Low dose SRL + weekly PegvisomantActive Control3 Interventions
Low dose of SRL monthly Octreotide LAR 10mg Lanreotide 60mg Weekly Pegvisomant (40-120mg/week)
Group II: High dose SRL + weekly PegvisomantActive Control3 Interventions
High dose of SRL monthly Octreotide LAR 30mg Lanreotide 120mg Weekly Pegvisomant (40-120mg/week)
Group III: Low dose SRL + daily PegvisomantActive Control3 Interventions
Low dose of SRL monthly Octreotide LAR 10mg Lanreotide 60mg Daily Pegvisomant (15-60mg/day)

Find a Location

Who is running the clinical trial?

Cedars-Sinai Medical CenterLead Sponsor
500 Previous Clinical Trials
164,787 Total Patients Enrolled
8 Trials studying Acromegaly
287 Patients Enrolled for Acromegaly
Shlomo Melmed, MDPrincipal Investigator - Cedars-Sinai Medical Center
Cedars-Sinai Medical Center, Sound Physicians Platinum Group Pc
University Of Cape Town (Medical School)
7 Previous Clinical Trials
1,475 Total Patients Enrolled
2 Trials studying Acromegaly
163 Patients Enrolled for Acromegaly

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby May 2025